Journal article
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
Blood, Vol.136(7), pp.857-870
08/13/2020
DOI: 10.1182/blood.2019003257
PMCID: PMC7426646
PMID: 32403132
Abstract
Immunomodulatory drugs, such as thalidomide and related compounds, potentiate T-cell effector functions. Cereblon (CRBN), a substrate receptor of the DDB1-cullin-RING E3 ubiquitin ligase complex, is the only molecular target for this drug class, where drug-induced, ubiquitin-dependent degradation of known "neosubstrates," such as IKAROS, AIOLOS, and CK1α, accounts for their biological activity. Far less clear is whether these CRBN E3 ligase-modulating compounds disrupt the endogenous functions of CRBN. We report that CRBN functions in a feedback loop that harnesses antigen-specific CD8+ T-cell effector responses. Specifically, Crbn deficiency in murine CD8+ T cells augments their central metabolism manifested as elevated bioenergetics, with supraphysiological levels of polyamines, secondary to enhanced glucose and amino acid transport, and with increased expression of metabolic enzymes, including the polyamine biosynthetic enzyme ornithine decarboxylase. Treatment with CRBN-modulating compounds similarly augments central metabolism of human CD8+ T cells. Notably, the metabolic control of CD8+ T cells by modulating compounds or Crbn deficiency is linked to increased and sustained expression of the master metabolic regulator MYC. Finally, Crbn-deficient T cells have augmented antigen-specific cytolytic activity vs melanoma tumor cells, ex vivo and in vivo, and drive accelerated and highly aggressive graft-versus-host disease. Therefore, CRBN functions to harness the activation of CD8+ T cells, and this phenotype can be exploited by treatment with drugs.
Details
- Title: Subtitle
- Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
- Creators
- Rebecca S Hesterberg - University of South FloridaMatthew S Beatty - Moffitt Cancer CenterYing Han - Tianjin Medical University Cancer Institute and HospitalMario R Fernandez - Moffitt Cancer CenterAfua A Akuffo - University of South FloridaWilliam E Goodheart - Moffitt Cancer CenterChunying Yang - Moffitt Cancer CenterShiun Chang - University of South FloridaChristelle M Colin - Moffitt Cancer CenterAileen Y Alontaga - Moffitt Cancer CenterJessica M McDaniel - Moffitt Cancer CenterAdam W Mailloux - Moffitt Cancer CenterJulia M R Billington - University of South FloridaLanzhu Yue - Tianjin Medical University General HospitalShonagh Russell - University of South FloridaRobert J Gillies - Department of Cancer Physiology.Sang Y Yun - Core Laboratories (United States)Muhammad Ayaz - Core Laboratories (United States)Nicholas J Lawrence - Moffitt Cancer CenterHarshani R Lawrence - Core Laboratories (United States)Xue-Zhong Yu - Medical University of South CarolinaJianing Fu - Medical University of South CarolinaLancia N Darville - Moffitt Cancer CenterJohn M Koomen - Moffitt Cancer CenterXiubao Ren - Tianjin Medical University Cancer Institute and HospitalJane Messina - Moffitt Cancer CenterKun Jiang - Moffitt Cancer CenterTimothy J Garrett - University of FloridaAnjali M Rajadhyaksha - Cornell UniversityJohn L Cleveland - Moffitt Cancer CenterPearlie K Epling-Burnette - Moffitt Cancer Center
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.136(7), pp.857-870
- DOI
- 10.1182/blood.2019003257
- PMID
- 32403132
- PMCID
- PMC7426646
- NLM abbreviation
- Blood
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Grant note
- F32 CA203217 / NCI NIH HHS P50 CA168536 / NCI NIH HHS R50 CA211447 / NCI NIH HHS P30 CA076292 / NCI NIH HHS
- Language
- English
- Date published
- 08/13/2020
- Academic Unit
- Microbiology and Immunology
- Record Identifier
- 9984297429102771
Metrics
19 Record Views